Home Healthcare Medical Devices Alpha Emitter Market

Alpha Emitter Market Size, Share & Trends Analysis Report By Type of Radionuclide (Astatine-211, Radium-223, Actinium-225, Lead-212, Bismuth-212, Other Radionuclides), By Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, Other Applications), By End User (Hospitals, Diagnostic Centers, Other End Users) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 13, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR3555DR | Pages: 140
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Alpha Emitter Market, By Type of Radionuclide 2022-2034 (USD MILLION/ Units)
    1. Astatine-211
    2. Radium-223
    3. Actinium-225
    4. Lead-212
    5. Bismuth-212
    6. Other Radionuclides
  2. Alpha Emitter Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Prostate Cancer
    2. Bone Metastasis
    3. Ovarian Cancer
    4. Pancreatic Cancer
    5. Endocrine Tumors
    6. Other Applications
  3. Alpha Emitter Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Diagnostic Centers
    3. Other End Users
  4. Regional Alpha Emitter Market
    1. North America
      1. North America Alpha Emitter Market By Type of Radionuclide 2022-2034 (USD MILLION/ Units)
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
      2. North America Alpha Emitter Market By Application 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bone Metastasis
        3. Ovarian Cancer
        4. Pancreatic Cancer
        5. Endocrine Tumors
        6. Other Applications
      3. North America Alpha Emitter Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Centers
        3. Other End Users
      4. U.S.
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      5. Canada
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
    2. Europe
      1. Europe Alpha Emitter Market By Type of Radionuclide 2022-2034 (USD MILLION/ Units)
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
      2. Europe Alpha Emitter Market By Application 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bone Metastasis
        3. Ovarian Cancer
        4. Pancreatic Cancer
        5. Endocrine Tumors
        6. Other Applications
      3. Europe Alpha Emitter Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Centers
        3. Other End Users
      4. U.K.
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      5. Germany
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      6. France
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      7. Spain
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      8. Italy
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      9. Russia
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      10. Nordic
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      11. Benelux
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      12. Rest of Europe
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
    3. APAC
      1. APAC Alpha Emitter Market By Type of Radionuclide 2022-2034 (USD MILLION/ Units)
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
      2. APAC Alpha Emitter Market By Application 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bone Metastasis
        3. Ovarian Cancer
        4. Pancreatic Cancer
        5. Endocrine Tumors
        6. Other Applications
      3. APAC Alpha Emitter Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Centers
        3. Other End Users
      4. China
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      5. Korea
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      6. Japan
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      7. India
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      8. Australia
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      9. Taiwan
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      10. South East Asia
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      11. Rest of Asia-Pacific
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
    4. Middle East and Africa
      1. Middle East and Africa Alpha Emitter Market By Type of Radionuclide 2022-2034 (USD MILLION/ Units)
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
      2. Middle East and Africa Alpha Emitter Market By Application 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bone Metastasis
        3. Ovarian Cancer
        4. Pancreatic Cancer
        5. Endocrine Tumors
        6. Other Applications
      3. Middle East and Africa Alpha Emitter Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Centers
        3. Other End Users
      4. UAE
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      5. Turkey
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      6. Saudi Arabia
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      7. South Africa
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      8. Egypt
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      9. Nigeria
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      10. Rest of MEA
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
    5. LATAM
      1. LATAM Alpha Emitter Market By Type of Radionuclide 2022-2034 (USD MILLION/ Units)
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
      2. LATAM Alpha Emitter Market By Application 2022-2034 (USD MILLION/ Units)
        1. Prostate Cancer
        2. Bone Metastasis
        3. Ovarian Cancer
        4. Pancreatic Cancer
        5. Endocrine Tumors
        6. Other Applications
      3. LATAM Alpha Emitter Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Diagnostic Centers
        3. Other End Users
      4. Brazil
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      5. Mexico
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      6. Argentina
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      7. Chile
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      8. Colombia
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
      9. Rest of LATAM
        1. Astatine-211
        2. Radium-223
        3. Actinium-225
        4. Lead-212
        5. Bismuth-212
        6. Other Radionuclides
        7. Prostate Cancer
        8. Bone Metastasis
        9. Ovarian Cancer
        10. Pancreatic Cancer
        11. Endocrine Tumors
        12. Other Applications
        13. Hospitals
        14. Diagnostic Centers
        15. Other End Users
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.